Do analysts prefer KZIA or CDIO?

Novogen presently has a consensus price target of $21.00, indicating a potential upside of 91.69%. Given Novogen's stronger consensus rating and higher probable upside, research analysts clearly believe Novogen is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, KZIA or CDIO?

Cardio Diagnostics has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 431.16 -$13.41M N/A N/A Cardio Diagnostics $10K 589.34 -$6.50M -$3.38 N/A

Do analysts recommend CDIO or QNCX?

Quince Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 5,946.51%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71

Do analysts prefer CDIO or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate CTXR or CDIO?

Citius Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 775.66%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate AEON or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Cardio Diagnostics (CDIO) Competitors

$1.99 -0.12 (-5.64%)

As of 11:37 AM Eastern

Compare

CDIO vs. KZIA, QNCX, ANEB, CTXR, and AEON

Should you buy Cardio Diagnostics stock or one of its competitors? MarketBeat compares Cardio Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardio Diagnostics include Novogen (KZIA), Quince Therapeutics (QNCX), Anebulo Pharmaceuticals (ANEB), Citius Pharmaceuticals (CTXR), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical products" industry.

How does Cardio Diagnostics compare to Novogen?

Novogen (NASDAQ:KZIA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Cardio Diagnostics has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	431.16	-$13.41M	N/A	N/A
Cardio Diagnostics	$10K	589.34	-$6.50M	-$3.38	N/A

Novogen has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Novogen's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Novogen has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, meaning that its stock price is 124% more volatile than the broader market.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Novogen presently has a consensus price target of $21.00, indicating a potential upside of 91.69%. Given Novogen's stronger consensus rating and higher probable upside, research analysts clearly believe Novogen is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Novogen had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 1 mentions for Novogen and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.02 beat Novogen's score of 0.94 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Positive
Cardio Diagnostics	Positive

Summary

Novogen beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.

How does Cardio Diagnostics compare to Quince Therapeutics?

Cardio Diagnostics (NASDAQ:CDIO) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 13.3% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cardio Diagnostics has higher revenue and earnings than Quince Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	589.34	-$6.50M	-$3.38	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

Quince Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 5,946.51%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Quince Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Cardio Diagnostics' return on equity of -78.82% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Quince Therapeutics	N/A	-372.88%	-67.99%

Cardio Diagnostics has a beta of 2.24, meaning that its stock price is 124% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

In the previous week, Quince Therapeutics had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 1 mentions for Quince Therapeutics and 0 mentions for Cardio Diagnostics. Quince Therapeutics' average media sentiment score of 1.80 beat Cardio Diagnostics' score of 1.02 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardio Diagnostics	Positive
Quince Therapeutics	Very Positive

Summary

Quince Therapeutics beats Cardio Diagnostics on 8 of the 14 factors compared between the two stocks.

How does Cardio Diagnostics compare to Anebulo Pharmaceuticals?

Cardio Diagnostics (NASDAQ:CDIO) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Anebulo Pharmaceuticals' return on equity of -74.57% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Cardio Diagnostics has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, indicating that its share price is 288% less volatile than the broader market.

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 13.3% of Cardio Diagnostics shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cardio Diagnostics has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	589.34	-$6.50M	-$3.38	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Cardio Diagnostics' average media sentiment score of 1.02 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Positive
Anebulo Pharmaceuticals	Neutral

Summary

Anebulo Pharmaceuticals beats Cardio Diagnostics on 7 of the 12 factors compared between the two stocks.

How does Cardio Diagnostics compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Cardio Diagnostics has lower revenue, but higher earnings than Citius Pharmaceuticals. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	$5.61M	2.79	-$37.43M	-$2.13	N/A
Cardio Diagnostics	$10K	589.34	-$6.50M	-$3.38	N/A

Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.02 beat Citius Pharmaceuticals' score of 0.94 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Positive
Cardio Diagnostics	Positive

Citius Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 775.66%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Citius Pharmaceuticals has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Citius Pharmaceuticals' return on equity of -61.09% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Summary

Citius Pharmaceuticals beats Cardio Diagnostics on 11 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Cardio Diagnostics has higher revenue and earnings than AEON Biopharma. Cardio Diagnostics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Cardio Diagnostics	$10K	589.34	-$6.50M	-$3.38	N/A

AEON Biopharma has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, AEON Biopharma had 3 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for AEON Biopharma and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.02 beat AEON Biopharma's score of 0.64 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
AEON Biopharma	Positive
Cardio Diagnostics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AEON Biopharma has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. AEON Biopharma's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Summary

AEON Biopharma beats Cardio Diagnostics on 8 of the 15 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.99M	$3.36B	$6.50B	$12.22B
Dividend Yield	N/A	2.36%	2.69%	5.31%
P/E Ratio	-0.60	18.89	23.86	24.04
Price / Sales	589.34	179.80	495.07	91.24
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	0.52	6.68	9.94	6.56
Net Income	-$6.50M	$24.09M	$3.56B	$337.00M
7 Day Performance	5.34%	-5.08%	-1.93%	-1.45%
1 Month Performance	8.80%	-1.46%	1.27%	2.18%
1 Year Performance	-55.95%	46.20%	27.45%	31.54%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	0.8961 of 5 stars	$1.99 -5.6%	N/A	-57.7%	$5.99M	$10K	N/A	1	Positive News Gap Down
KZIA Novogen	2.3466 of 5 stars	$12.60 +0.7%	$21.00 +66.7%	+112.7%	$20.82M	$42K	N/A	12
QNCX Quince Therapeutics	2.1353 of 5 stars	$1.26 +5.3%	$65.00 +5,042.4%	-89.9%	$20.46M	N/A	N/A	60	Positive News
ANEB Anebulo Pharmaceuticals	N/A	$0.50 flat	N/A	-61.9%	$20.39M	N/A	N/A	4	Gap Up
CTXR Citius Pharmaceuticals	3.1316 of 5 stars	$0.72 +3.7%	$5.00 +591.6%	-32.6%	$19.88M	$5.61M	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. KZIA, QNCX, ANEB, CTXR, and AEON

How does Cardio Diagnostics compare to Novogen?

Summary

How does Cardio Diagnostics compare to Quince Therapeutics?

Summary

How does Cardio Diagnostics compare to Anebulo Pharmaceuticals?

Summary

How does Cardio Diagnostics compare to Citius Pharmaceuticals?

Summary

How does Cardio Diagnostics compare to AEON Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. KZIA, QNCX, ANEB, CTXR, and AEON

How does Cardio Diagnostics compare to Novogen?

Which has better earnings and valuation, KZIA or CDIO?

Is KZIA or CDIO more profitable?

Which has more volatility & risk, KZIA or CDIO?

Do insiders and institutionals believe in KZIA or CDIO?

Do analysts prefer KZIA or CDIO?

Does the media refer more to KZIA or CDIO?

Summary

How does Cardio Diagnostics compare to Quince Therapeutics?

Do insiders & institutionals hold more shares of CDIO or QNCX?

Which has stronger earnings & valuation, CDIO or QNCX?

Do analysts recommend CDIO or QNCX?

Is CDIO or QNCX more profitable?

Which has more volatility & risk, CDIO or QNCX?

Does the media prefer CDIO or QNCX?

Summary

How does Cardio Diagnostics compare to Anebulo Pharmaceuticals?

Is CDIO or ANEB more profitable?

Which has more risk & volatility, CDIO or ANEB?

Do institutionals and insiders believe in CDIO or ANEB?

Which has preferable valuation & earnings, CDIO or ANEB?

Do analysts prefer CDIO or ANEB?

Does the media prefer CDIO or ANEB?

Summary

How does Cardio Diagnostics compare to Citius Pharmaceuticals?

Which has preferable valuation & earnings, CTXR or CDIO?

Which has more risk and volatility, CTXR or CDIO?

Do institutionals & insiders believe in CTXR or CDIO?

Does the media refer more to CTXR or CDIO?

Do analysts rate CTXR or CDIO?

Is CTXR or CDIO more profitable?

Summary

How does Cardio Diagnostics compare to AEON Biopharma?

Which has preferable valuation & earnings, AEON or CDIO?

Which has more risk and volatility, AEON or CDIO?

Do institutionals & insiders believe in AEON or CDIO?

Does the media refer more to AEON or CDIO?

Do analysts rate AEON or CDIO?

Is AEON or CDIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools